Retrospective analysis of a gabapentin high dose taper compared to lorazepam in acute inpatient alcohol withdrawal. (4th July 2019)
- Record Type:
- Journal Article
- Title:
- Retrospective analysis of a gabapentin high dose taper compared to lorazepam in acute inpatient alcohol withdrawal. (4th July 2019)
- Main Title:
- Retrospective analysis of a gabapentin high dose taper compared to lorazepam in acute inpatient alcohol withdrawal
- Authors:
- Morrison, Matthew
Udeh, Elizabeth
Burak, Michelle - Abstract:
- ABSTRACT: Background : Benzodiazepines have remained the standard of care for alcohol withdrawal syndrome; however, they have numerous unfavorable physiologic effects. Gabapentin has limited data to support a benefit in reducing benzodiazepine usage in alcohol withdrawal syndrome. Objectives : Evaluate the association of an institutional guideline and order set for alcohol withdrawal that incorporates high dose gabapentin tapers in acutely withdrawing patients. Methods : This retrospective study evaluated patients experiencing acute alcohol withdrawal. Two time periods were evaluated: a pre-protocol group assessed outcomes prior to implementation of a gabapentin backbone taper-based guideline (PRE-implementation), and a post-protocol group assessed post-guideline and order set introduction (POST-implementation). A total of 100 patients (50 PRE-implementation and 50 POST-implementation; 84% male, 16% female) were included in the analysis. Results : There was a significant difference in the median daily lorazepam usage in the PRE-implementation versus POST-implementation groups (9.48 [5.58–28.46] vs 6.52 [3.84–11.65] mg, P = 0.024) with a reduction observed in the POST-implementation group. There was also a significant difference in the mean hospital length of stay (LOS) in the PRE-implementation versus POST-implementation groups (9.92 ± 7.33 vs 7.04 ± 4.59 days, P = 0.021) in favor of the POST-implementation group. There was no difference in the number of rapid responsesABSTRACT: Background : Benzodiazepines have remained the standard of care for alcohol withdrawal syndrome; however, they have numerous unfavorable physiologic effects. Gabapentin has limited data to support a benefit in reducing benzodiazepine usage in alcohol withdrawal syndrome. Objectives : Evaluate the association of an institutional guideline and order set for alcohol withdrawal that incorporates high dose gabapentin tapers in acutely withdrawing patients. Methods : This retrospective study evaluated patients experiencing acute alcohol withdrawal. Two time periods were evaluated: a pre-protocol group assessed outcomes prior to implementation of a gabapentin backbone taper-based guideline (PRE-implementation), and a post-protocol group assessed post-guideline and order set introduction (POST-implementation). A total of 100 patients (50 PRE-implementation and 50 POST-implementation; 84% male, 16% female) were included in the analysis. Results : There was a significant difference in the median daily lorazepam usage in the PRE-implementation versus POST-implementation groups (9.48 [5.58–28.46] vs 6.52 [3.84–11.65] mg, P = 0.024) with a reduction observed in the POST-implementation group. There was also a significant difference in the mean hospital length of stay (LOS) in the PRE-implementation versus POST-implementation groups (9.92 ± 7.33 vs 7.04 ± 4.59 days, P = 0.021) in favor of the POST-implementation group. There was no difference in the number of rapid responses called, median intensive care unit (ICU) LOS, median number of days the patient was confusion assessment method for the ICU (CAM-ICU) positive or number of transfers to a higher level of care. Conclusions : Implementation of an institutional guideline and order set for alcohol withdrawal incorporating high dose gabapentin tapers was associated with a decreased median daily lorazepam use as well as hospital LOS; however, retrospective design and inherent limitations require larger prospective trials to validate results. … (more)
- Is Part Of:
- American journal of drug and alcohol abuse. Volume 45:Number 4(2019:Jul.)
- Journal:
- American journal of drug and alcohol abuse
- Issue:
- Volume 45:Number 4(2019:Jul.)
- Issue Display:
- Volume 45, Issue 4 (2019)
- Year:
- 2019
- Volume:
- 45
- Issue:
- 4
- Issue Sort Value:
- 2019-0045-0004-0000
- Page Start:
- 385
- Page End:
- 391
- Publication Date:
- 2019-07-04
- Subjects:
- Alcohol withdrawal -- alcoholism -- benzodiazepine -- anticonvulsant -- gabapentin -- inpatient
Drug abuse -- Treatment -- Periodicals
Alcoholism -- Treatment -- Periodicals
Substance-abuse -- Treatment -- Periodicals
Alcoholism -- Periodicals
Substance-Related Disorders -- Periodicals
616.86 - Journal URLs:
- http://informahealthcare.com/loi/ada ↗
http://www.tandfonline.com/toc/iada20/current ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/00952990.2019.1602136 ↗
- Languages:
- English
- ISSNs:
- 0095-2990
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0824.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 10869.xml